Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of several types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. Co.'s DNA medicine candidates are made using its proprietary SynCon® technology that creates plasmids, which are circular strands of DNA that instruct a cell to produce the target antigen to help the person's immune system recognize and destroy cancerous or infected cells. The INO stock yearly return is shown above.
The yearly return on the INO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|